Related Experiment Video
Updated: Sep 20, 2025
Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
Published on: April 11, 2016
A Biomarker Signature-Guided Clinical Trial Design for Precision Medicine
Yuan Li1,2, Dejian Lai1, Ruosha Li1
1Department of Biostatistics and Data Science, The University of Texas Health Science Center at Houston, Houston, TX, USA.
Abstract:
Targeted cancer therapies aim to effectively treat patients with specific biomarker profiles. Nevertheless, these therapies may not always precisely hit their intended targets, leading to uncertainty about the specific subset of patients who will benefit. To address this uncertainty, the identification of sensitive patient subsets in clinical trials becomes crucial. Our proposed phase IIB/III clinical trial design seeks to pinpoint a biomarker signature with precision, ensuring the accurate identification of patients who will respond to a specific treatment. This approach allows for the selective enrollment of sensitive patients to maximize benefits for trial participants. We incorporate Bayesian methodology to facilitate response-adaptive randomization, enhancing the likelihood that each participant receives his/her optimal treatment. Furthermore, our design uses inverse-probability-of-treatment-weighted analysis to avoid selection bias and control for the type I error rate. The evaluation of this trial design is based on four criteria: the statistical power, response rate of all patients participating in the current trial, their individual loss, and probabilities of receiving their optimal treatment for both current trial participants and future patients. Simulations demonstrate the proposed design's potential for maximizing trial participants' benefits with little sacrifice on statistical power. Its key advantages include an improved overall response rate within the trial and a higher percentage of patients receiving the optimal treatment.
Insights
This study introduces a novel clinical trial design to precisely identify cancer patients likely to benefit from targeted therapies. The approach enhances treatment efficacy by ensuring participants receive their optimal therapy, improving outcomes.
Area of Science:
- Oncology
- Biostatistics
- Clinical Trial Design
Background:
- Targeted cancer therapies require precise patient selection based on biomarkers for optimal efficacy.
- Uncertainty exists regarding which patients will benefit from specific targeted therapies, necessitating improved clinical trial strategies.
- Identifying sensitive patient subsets is crucial for maximizing treatment benefits and trial success.
Purpose of the Study:
- To propose and evaluate a novel Phase IIB/III clinical trial design for precisely identifying biomarker signatures predictive of treatment response.
- To enhance patient stratification for targeted cancer therapies, ensuring enrollment of sensitive individuals.
- To maximize benefits for clinical trial participants by facilitating personalized treatment allocation.
Main Methods:
- Utilizing a Bayesian methodology for response-adaptive randomization to optimize individual treatment assignment.
- Implementing inverse-probability-of-treatment-weighted (IPTW) analysis to mitigate selection bias and control Type I error rates.
- Evaluating the design based on statistical power, overall response rate, individual patient loss, and optimal treatment probabilities.
Main Results:
- Simulations indicate the proposed design effectively maximizes participant benefits with minimal compromise on statistical power.
- The design demonstrated potential for an improved overall response rate within the trial population.
- A higher percentage of patients were identified as receiving their optimal treatment under the proposed design.
Conclusions:
- The novel clinical trial design offers a precise method for identifying responsive patient subsets for targeted cancer therapies.
- Response-adaptive randomization and IPTW analysis enhance treatment allocation and control statistical errors.
- This approach promises improved clinical trial efficiency and better patient outcomes in precision oncology.
More Related Videos
07:40Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
Published on: March 20, 2021
05:53Candidate Gene Testing in Clinical Cohort Studies with Multiplexed Genotyping and Mass Spectrometry
Published on: June 21, 2018
